Lupin Receives Approval From U.S. FDA For Metoprolol Succinate Extended-Release Tablets USP

Global pharma major Lupin Limited (Lupin) on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Metoprolol Succinate Extended-Release Tablets USP, 25 mg, 50 mg, 100 mg, and 200 mg, to market a generic equivalent of Toprol-XL® Tablets, 25 mg, 50 mg, 100 mg and 200 mg of Sequel Therapeutics, LLC, the company announced through an exchange filing.

The product will be manufactured at Lupin’s Pithampur facility in India.

Metoprolol Succinate Extended-Release Tablets USP (RLD Toprol-XL®) had estimated annual sales of USD 305 million in the U.S.

Lupin Limited shares

FPJ Shorts

WATCH: Man Flaunts Sensational Moves As He Dances To 'Chammak Challo' Outside Shah Rukh Khan's Mannat Residence In Mumbai

'One Of The Dumbest...': Jamie Smith's Dismissal Draws Sharp Criticism From Justin Langer During AUS vs ENG, 5th Ashes Test; VIDEO

'Satyamev Jayate': BJP's Shehzad Poonawalla After SC Denies Bail To Umar Khalid, Sharjeel Imam In Delhi Riots Case; Accuses Cong Of Supporting 'Tukde Tukde Gang'

'Proud Of Your Contributions': Vheda Health CEO Praised Nikitha Rao Godishala, Who Was Killed By Her Ex-Boyfriend In US; Know About Her Work Profile & Education

The shares of Lupin on Wednesday at 3:30pm were at Rs 1,113.50, up by 2.91 percent.

Read Also

Lupin Receives Approval From U.S. FDA For Bromfenac Ophthalmic Solution